Jackie D. Corbin
#119,438
Most Influential Person Now
Jackie D. Corbin's AcademicInfluence.com Rankings
Jackie D. Corbinphilosophy Degrees
Philosophy
#5353
World Rank
#8122
Historical Rank
Ontology
#38
World Rank
#46
Historical Rank
Download Badge
Philosophy
Why Is Jackie D. Corbin Influential?
(Suggest an Edit or Addition)Jackie D. Corbin's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- cGMP-Dependent Protein Kinases and cGMP Phosphodiesterases in Nitric Oxide and cGMP Action (2010) (835)
- The distribution and dissociation of cyclic adenosine 3':5'-monophosphate-dependent protein kinases in adipose, cardiac, and other tissues. (1975) (603)
- Cyclic nucleotide phosphodiesterases: relating structure and function. (2001) (562)
- Mammalian cyclic nucleotide phosphodiesterases: molecular mechanisms and physiological functions. (2011) (530)
- Tissue distribution of phosphodiesterase families and the effects of sildenafil on tissue cyclic nucleotides, platelet function, and the contractile responses of trabeculae carneae and aortic rings in vitro. (1999) (515)
- Cyclic GMP Phosphodiesterase-5: Target of Sildenafil* (1999) (505)
- Structure and function of cyclic nucleotide-dependent protein kinases. (1994) (438)
- Assay of cyclic AMP-dependent protein kinases. (1974) (342)
- Studies on the properties and mode of action of the purified regulatory subunit of bovine heart adenosine 3':5'-monophosphate-dependent protein kinase. (1978) (338)
- Cyclic nucleotide-dependent protein kinases: intracellular receptors for cAMP and cGMP action. (1999) (316)
- Compartmentalization of adenosine 3':5'-monophosphate and adenosine 3':5'-monophosphate-dependent protein kinase in heart tissue. (1977) (296)
- Regulatory mechanisms in the control of protein kinases. (1982) (282)
- Direct evidence for cross-activation of cGMP-dependent protein kinase by cAMP in pig coronary arteries. (1992) (281)
- Phosphorylation of phosphodiesterase-5 by cyclic nucleotide-dependent protein kinase alters its catalytic and allosteric cGMP-binding activities. (2000) (274)
- Interaction of glucocorticoids with glucagon and epinephrine in the control of gluconeogenesis and glycogenolysis in liver and of lipolysis in adipose tissue. (1972) (239)
- Stimulation of intestinal Cl- transport by heat-stable enterotoxin: activation of cAMP-dependent protein kinase by cGMP. (1992) (235)
- Characterization of a purified bovine lung cGMP-binding cGMP phosphodiesterase. (1990) (232)
- Relaxation of vascular and tracheal smooth muscle by cyclic nucleotide analogs that preferentially activate purified cGMP-dependent protein kinase. (1988) (227)
- Isolation and characterization of cDNAs encoding PDE5A, a human cGMP-binding, cGMP-specific 3',5'-cyclic nucleotide phosphodiesterase. (1998) (216)
- Dual ion-channel regulation by cyclic GMP and cyclic GMP-dependent protein kinase (1990) (208)
- Cyclic nucleotide-binding domains in proteins having diverse functions. (1992) (196)
- Mechanisms of action of PDE5 inhibition in erectile dysfunction (2004) (195)
- High lung PDE5: a strong basis for treating pulmonary hypertension with PDE5 inhibitors. (2005) (193)
- Separation of regulatory and catalytic subunits of the cyclic 3',5'-adenosine monophosphate-dependent protein kinase(s) of rabbit skeletal muscle. (1971) (190)
- Purification and characterization of the catalytic subunit of adenosine 3':5'-cyclic monophosphate-dependent protein kinase from bovine liver. (1976) (183)
- Inhibition of cyclic GMP-binding cyclic GMP-specific phosphodiesterase (Type 5) by sildenafil and related compounds. (1999) (181)
- Regulation of adenosine 3',5'-monophosphate-dependent protein kinase. I. Preliminary characterization of the adipose tissue enzyme in crude extracts. (1973) (180)
- Binding of tritiated sildenafil, tadalafil, or vardenafil to the phosphodiesterase-5 catalytic site displays potency, specificity, heterogeneity, and cGMP stimulation. (2004) (172)
- Phosphodiesterase type 5 as a pharmacologic target in erectile dysfunction. (2002) (171)
- The structure of a bovine lung cGMP-binding, cGMP-specific phosphodiesterase deduced from a cDNA clone. (1993) (167)
- Characterization of a novel cGMP binding protein from rat lung. (1980) (167)
- Activation of adipose tissue lipase by skeletal muscle cyclic adenosine 3',5'- monophosphate-stimulated protein kinase. (1970) (165)
- Characterization and regulation of heart adenosine 3':5'-monophosphate-dependent protein kinase isozymes. (1977) (160)
- Substrate- and kinase-directed regulation of phosphorylation of a cGMP-binding phosphodiesterase by cGMP. (1990) (156)
- Properties and functions of GAF domains in cyclic nucleotide phosphodiesterases and other proteins. (2004) (150)
- Characterization of a novel isozyme of cGMP-dependent protein kinase from bovine aorta. (1989) (150)
- Regulation of adenosine 3',5'-monophosphate-dependent protein kinase. II. Hormonal regulation of the adipose tissue enzyme. (1973) (149)
- Regulation of adenosine 3:5-monophosphate-dependent protein kinase. (1975) (142)
- Zinc interactions and conserved motifs of the cGMP-binding cGMP-specific phosphodiesterase suggest that it is a zinc hydrolase. (1994) (137)
- A cyclic AMP--stimulated protein kinase in adipose tissue. (1969) (134)
- Two different intrachain cAMP binding sites of cAMP-dependent protein kinases. (1980) (134)
- Pharmacotherapy for erectile dysfunction. (2004) (131)
- Studies on the alpha-andrenergic activation of hepatic glucose output. II. Investigation of the roles of adenosine 3':5'-monophosphate and adenosine 3':5'-monophosphate-dependent protein kinase in the actions of phenylephrine in isolated hepatocytes. (1976) (129)
- Two classes of cAMP analogs which are selective for the two different cAMP-binding sites of type II protein kinase demonstrate synergism when added together to intact adipocytes. (1984) (127)
- Interrupted Glucagon Signaling Reveals Hepatic α Cell Axis and Role for L-Glutamine in α Cell Proliferation. (2017) (122)
- Adenosine 3':5'-cyclic monophosphate-binding proteins in bovine and rat tissues. (1976) (120)
- Crystal Structures of Phosphodiesterases 4 and 5 in Complex with Inhibitor 3-Isobutyl-1-methylxanthine Suggest a Conformation Determinant of Inhibitor Selectivity* (2004) (115)
- Purification and subunit composition of guanosine 3':5'-monophosphate-dependent protein kinase from bovine lung. (1977) (113)
- Studies of cGMP analog specificity and function of the two intrasubunit binding sites of cGMP-dependent protein kinase. (1986) (112)
- Structural and Functional Features in Human PDE5A1 Regulatory Domain That Provide for Allosteric cGMP Binding, Dimerization, and Regulation* (2005) (111)
- 3 Cyclic Nucleotide-Dependent Protein Kinases (1986) (110)
- Guanosine 3':5'-cyclic monophosphate binding proteins in rat tissues. (1976) (110)
- Predicted structures of the cGMP binding domains of the cGMP-dependent protein kinase: a key alanine/threonine difference in evolutionary divergence of cAMP and cGMP binding sites. (1989) (109)
- The Type II Isoform of cGMP-dependent Protein Kinase Is Dimeric and Possesses Regulatory and Catalytic Properties Distinct from the Type I Isoforms (*) (1995) (106)
- Relaxation of pig coronary arteries by new and potent cGMP analogs that selectively activate type I alpha, compared with type I beta, cGMP-dependent protein kinase. (1992) (106)
- Testicular adenosine 3':5'-monophosphate-dependent protein kinase. Regulation by follicle-stimulating hormone. (1974) (98)
- Adenosine 3':5'-cyclic monophosphate- and guanosine 3':5'-cyclic monophosphate-dependent protein kinases: possible homologous proteins. (1977) (96)
- An Essential Aspartic Acid at Each of Two Allosteric cGMP-binding Sites of a cGMP-specific Phosphodiesterase (*) (1995) (95)
- Multiple Conformations of Phosphodiesterase-5 (2006) (95)
- ANF elicits phosphorylation of the cGMP phosphodiesterase in vascular smooth muscle cells. (1998) (95)
- Activation of protein kinase isozymes by cyclic nucleotide analogs used singly or in combination. Principles for optimizing the isozyme specificity of analog combinations. (1985) (94)
- Binding of cGMP to both allosteric sites of cGMP-binding cGMP-specific phosphodiesterase (PDE5) is required for its phosphorylation. (1998) (93)
- Phosphorylation of Isolated Human Phosphodiesterase-5 Regulatory Domain Induces an Apparent Conformational Change and Increases cGMP Binding Affinity* (2002) (92)
- Interaction of the subunits of adenosine 3':5'-cyclic monophosphate-dependent protein kinase of muscle. (1971) (89)
- Autophosphorylation of Type Iβ cGMP-dependent Protein Kinase Increases Basal Catalytic Activity and Enhances Allosteric Activation by cGMP or cAMP* (1996) (89)
- Activation of cyclic AMP-dependent kinase is required but may not be sufficient to mimic cyclic AMP-dependent DNA synthesis and thyroglobulin expression in dog thyroid cells (1997) (85)
- Discriminative insulin antagonism of stimulatory effects of various cAMP analogs on adipocyte lipolysis and hepatocyte glycogenolysis. (1985) (84)
- Allosteric sites of phosphodiesterase-5 (PDE5) (2001) (84)
- Molecular mechanisms and pharmacokinetics of phosphodiesterase-5 antagonists (2003) (83)
- Progress in understanding the mechanism and function of cyclic GMP-dependent protein kinase. (1994) (83)
- [3H]sildenafil binding to phosphodiesterase-5 is specific, kinetically heterogeneous, and stimulated by cGMP. (2003) (81)
- Studies of two different intrachain cGMP-binding sites of cGMP-dependent protein kinase. (1983) (81)
- Mechanisms associated with cGMP binding and activation of cGMP-dependent protein kinase (2003) (79)
- Vardenafil: structural basis for higher potency over sildenafil in inhibiting cGMP-specific phosphodiesterase-5 (PDE5) (2004) (78)
- Precision Substrate Targeting of Protein Kinases (1996) (78)
- Probable involvement of both intrachain cAMP binding sites in activation of protein kinase. (1983) (77)
- A phenylalanine in peptide substrates provides for selectivity between cGMP- and cAMP-dependent protein kinases. (1992) (77)
- Identifying the cholesterol binding domain in the nicotinic acetylcholine receptor with [125I]azido-cholesterol. (1998) (76)
- Studies on the structure and mechanism of activation of the guanosine 3':5'-monophosphate-dependent protein kinase. (1978) (74)
- Cross-activation: overriding cAMP/cGMP selectivities of protein kinases in tissues. (1992) (74)
- On the question of translocation of heart cAMP-dependent protein kinase. (1975) (74)
- Sildenafil citrate does not affect cardiac contractility in human or dog heart (2003) (71)
- Purification of cGMP-binding protein phosphodiesterase from rat lung. (1988) (70)
- Adenosine 3',5'-monophosphate-dependent protein kinase from adipose tissue. (1972) (70)
- Potential Roles of Conserved Amino Acids in the Catalytic Domain of the cGMP-binding cGMP-specific Phosphodiesterase (PDE5)* (1998) (70)
- Expression of an Active, Monomeric Catalytic Domain of the cGMP-binding cGMP-specific Phosphodiesterase (PDE5)* (1999) (69)
- In vivo and in vitro phosphorylation of rat liver fructose-1,6-bisphosphatase. (1977) (68)
- Identification of Key Amino Acids in a Conserved cGMP-binding Site of cGMP-binding Phosphodiesterases (1996) (68)
- One amino acid change produces a high affinity cGMP-binding site in cAMP-dependent protein kinase. (1990) (68)
- cGMP-Hydrolytic Activity and Its Inhibition by Sildenafil in Normal and Failing Human and Mouse Myocardium (2009) (67)
- Short-term feedback regulation of cAMP by accelerated degradation in rat tissues. (1987) (65)
- Inhibition of cyclic nucleotide phosphodiesterases by methylxanthines and related compounds. (2011) (63)
- Expression and characterization of mutant forms of the type I regulatory subunit of cAMP-dependent protein kinase. The effect of defective cAMP binding on holoenzyme activation. (1989) (62)
- Activation of the particulate low Km phosphodiesterase of adipocytes by addition of cAMP-dependent protein kinase. (1988) (60)
- Microheterogeneity of type II cAMP-dependent protein kinase in various mammalian species and tissues. (1984) (60)
- Molecular properties of mammalian proteins that interact with cGMP: protein kinases, cation channels, phosphodiesterases, and multi-drug anion transporters. (2005) (60)
- Mutating protein kinase cAMP-binding sites into cGMP-binding sites. Mechanism of cGMP selectivity. (1991) (59)
- Probing Domain Functions of Chimeric PDE6α′/PDE5 cGMP-Phosphodiesterase* (1998) (58)
- Progressive Cyclic Nucleotide-induced Conformational Changes in the cGMP-dependent Protein Kinase Studied by Small Angle X-ray Scattering in Solution* (1997) (57)
- Properties of a cGMP-dependent monomeric protein kinase from bovine aorta. (1989) (57)
- Purified cyclic GMP-dependent protein kinase catalyzes the phosphorylation of cardiac troponin inhibitory subunit (TN-1). (1978) (56)
- Fast and Slow Cyclic Nucleotide-dissociation Sites in cAMP-dependent Protein Kinase Are Transposed in Type Iβ cGMP-dependent Protein Kinase* (1996) (56)
- cAMP-dependent protein kinase activation lowers hepatocyte cAMP. (1985) (56)
- High biochemical selectivity of tadalafil, sildenafil and vardenafil for human phosphodiesterase 5A1 (PDE5) over PDE11A4 suggests the absence of PDE11A4 cross-reaction in patients (2005) (55)
- Use of synergistic pairs of site-selective cAMP analogs in intact cells. (1988) (54)
- Functional characterization of cAMP-binding mutations in type I protein kinase. (1989) (53)
- Activation by Autophosphorylation or cGMP Binding Produces a Similar Apparent Conformational Change in cGMP-dependent Protein Kinase* (1998) (50)
- Determination of the cAMP-dependent protein kinase activity ratio in intact tissues. (1983) (50)
- Autophosphorylation: a salient feature of protein kinases (1993) (50)
- Regulatory subunits of bovine heart and rabbit skeletal muscle cAMP-dependent protein kinase isozymes. (1983) (50)
- Studies on the adenosine 3',5'-monophosphate-dependent protein kinases of rabbit skeletal muscle. (1972) (49)
- Cytoskeletal disrupting agents prevent calmodulin kinase, iq domain and voltage‐dependent facilitation of l‐type ca2+ Channels (2002) (49)
- Studies on the function of the two intrachain cAMP binding sites of protein kinase. (1981) (49)
- Activation by Cyclic GMP Binding Causes an Apparent Conformational Change in cGMP-dependent Protein Kinase* (1997) (48)
- Dimerization of cGMP-dependent Protein Kinase Iβ Is Mediated by an Extensive Amino-terminal Leucine Zipper Motif, and Dimerization Modulates Enzyme Function* (2003) (48)
- Proteolytic solubilization and modification of hormone-sensitive cyclic nucleotide phosphodiesterase. (1980) (47)
- Molecular biology and pharmacology of PDE-5-inhibitor therapy for erectile dysfunction. (2003) (47)
- cGMP-dependent protein kinase Iα associates with the antidepressant-sensitive serotonin transporter and dictates rapid modulation of serotonin uptake (2009) (47)
- Regulatory subunit of cAMP-dependent protein kinase inhibits phosphoprotein phosphatase. (1985) (46)
- Interaction of acetylcholine and epinephrine on heart cyclic AMP-dependent protein kinase. (1978) (46)
- cAMP-dependent protein kinase, but not the cGMP-dependent enzyme, rapidly phosphorylates delta-CREB, and a synthetic delta-CREB peptide. (1992) (45)
- Pairs of cyclic AMP analogs, that are specifically synergistic for type I and type II cAMP-dependent protein kinases, mimic thyrotropin effects on the function, differentiation expression and mitogenesis of dog thyroid cells. (1989) (45)
- Molecular mechanisms that could contribute to prolonged effectiveness of PDE5 inhibitors to improve erectile function (2008) (44)
- Phosphorylation modulates the activity of glycine N-methyltransferase, a folate binding protein. In vitro phosphorylation is inhibited by the natural folate ligand. (1989) (44)
- Stimulation of serotonin transport by the cyclic GMP phosphodiesterase-5 inhibitor sildenafil. (2004) (43)
- Arginine 75 in the Pseudosubstrate Sequence of Type Iβ cGMPdependent Protein Kinase Is Critical for Autoinhibition, Although Autophosphorylated Serine 63 Is Outside This Sequence* (1996) (43)
- Development of a high throughput screen for allosteric modulators of melanocortin-4 receptor signaling using a real time cAMP assay. (2011) (42)
- Studies on functional domains of the regulatory subunit of bovine heart adenosine 3':5'-monophosphate-dependent protein kinase. (1980) (42)
- Effect of cyclic nucleotide analogs on intrachain site I of protein kinase isozymes. (1982) (42)
- ATP analog specificity of cAMP-dependent protein kinase, cGMP-dependent protein kinase, and phosphorylase kinase. (1984) (41)
- Sildenafil: efficacy, safety, tolerability and mechanism of action in treating erectile dysfunction (2005) (41)
- cGMP-dependent protein kinase protects cGMP from hydrolysis by phosphodiesterase-5. (2003) (40)
- Studies on the interactions between the cyclic nucleotide-binding sites of cGMP-dependent protein kinase. (1987) (39)
- Phosphodiesterase-5 inhibition: the molecular biology of erectile function and dysfunction. (2005) (39)
- Involvement of cAMP-dependent protein kinase in the regulation of heart contractile force. (1977) (39)
- Review of phosphodiesterases in the urogenital system: new directions for therapeutic intervention. (2004) (38)
- Some aspects of the phosphorylation of phenylalanine 4-monooxygenase by a calcium-dependent and calmodulin-dependent protein kinase. (1984) (38)
- Allosteric sites of phosphodiesterase-5 (PDE5). A potential role in negative feedback regulation of cGMP signaling in corpus cavernosum. (2001) (38)
- A Conserved Serine Juxtaposed to the Pseudosubstrate Site of Type I cGMP-dependent Protein Kinase Contributes Strongly to Autoinhibition and Lower cGMP Affinity* (2002) (36)
- PDE5 inhibitors: targeting erectile dysfunction in diabetics. (2011) (36)
- Mechanisms of autoinhibition in cyclic nucleotide-dependent protein kinases. (2002) (35)
- Cyclic GMP-hydrolyzing phosphodiesterases. (2009) (35)
- Hormonal regulation of adenosine 3',5'-monophosphate-dependent protein kinase. (1975) (35)
- Phosphorylation of smg p21B/rap1B p21 by cyclic GMP‐dependent protein kinase (1992) (34)
- N-Terminal domain of phosphodiesterase-11A4 (PDE11A4) decreases affinity of the catalytic site for substrates and tadalafil, and is involved in oligomerization. (2007) (34)
- Types I alpha and I beta isozymes of cGMP-dependent protein kinase: alternative mRNA splicing may produce different inhibitory domains. (1988) (34)
- Purification and assay of cAMP, cGMP, and cyclic nucleotide analogs in cells treated with cyclic nucleotide analogs. (1988) (34)
- Interconvertible cGMP-free and cGMP-bound forms of cGMP-dependent protein kinase in mammalian tissues. (1987) (33)
- Identification of Critical Determinants for Autoinhibition in the Pseudosubstrate Region of Type Iα cAMP-dependent Protein Kinase* (1997) (33)
- Alpha adrenergic involvement in heart metabolism: effects on adenosine cyclic 3',5'-monophosphate, adenosine cyclic 3',5'-monophosphate-dependent protein kinase, guanosine cyclic 3',5'-monophosphate, and glucose transport. (1977) (32)
- Phosphodiesterase-5 Gln817 Is Critical for cGMP, Vardenafil, or Sildenafil Affinity (2006) (32)
- Partial mapping of cyclic nucleotide sites and studies of regulatory mechanisms of phosphodiesterases using cyclic nucleotide analogues. (1992) (32)
- A 46-Amino Acid Segment in Phosphodiesterase-5 GAF-B Domain Provides for High Vardenafil Potency over Sildenafil and Tadalafil and Is Involved in Phosphodiesterase-5 Dimerization (2006) (31)
- Hydropathic analysis and mutagenesis of the catalytic domain of the cGMP-binding cGMP-specific phosphodiesterase (PDE5). cGMP versus cAMP substrate selectivity. (1998) (30)
- Purification and characterization of an inactive form of cAMP-dependent protein kinase containing bound cAMP. (1987) (30)
- Critical amino acids in phosphodiesterase-5 catalytic site that provide for high-affinity interaction with cyclic guanosine monophosphate and inhibitors. (2007) (29)
- Cyclic Nucleotide-Dependent Protein Kinases (2000) (29)
- ORIGINAL RESEARCH—PHOSPHODIESTERASE INHIBITOR THERAPY FOR ED: Pharmacotherapy for Erectile Dysfunction (2004) (29)
- Ligand-induced conformational changes in cyclic nucleotide phosphodiesterases and cyclic nucleotide-dependent protein kinases. (1998) (29)
- Characterization of small cAMP-binding fragments of cAMP-dependent protein kinases. (1979) (27)
- Distinguishing the Roles of the Two Different cGMP-binding Sites for Modulating Phosphorylation of Exogenous Substrate (Heterophosphorylation) and Autophosphorylation of cGMP-dependent Protein Kinase* (2000) (26)
- The regulatory subunit monomer of cAMP-dependent protein kinase retains the salient kinetic properties of the native dimeric subunit. (1985) (26)
- [26] Purification of type Iα and Type Iβ isozymes and proteolyzed type Iβ monomeric enzyme of cGMP-dependent protein kinase from bovine aorta (1991) (26)
- Single step isolation of sildenafil from commercially available Viagra™ tablets (2003) (24)
- Cyclic GMP specifically suppresses Type-Ialpha cGMP-dependent protein kinase expression by ubiquitination. (2009) (23)
- Histidine-607 and histidine-643 provide important interactions for metal support of catalysis in phosphodiesterase-5. (2000) (23)
- Phosphorylation of sites 3 and 4 in rabbit skeletal muscle glycogen synthase by cAMP-dependent protein kinase. (1985) (22)
- Conversion of Phosphodiesterase-5 (PDE5) Catalytic Site to Higher Affinity by PDE5 Inhibitors (2007) (21)
- Phosphodiesterase 5: Molecular Characteristics Relating to Structure, Function, and Regulation (2006) (21)
- New insights into cGMP action. (1990) (21)
- Perturbation and structural organization of the two intrachain cAMP binding sites of cAMP-dependent protein kinase II. (1981) (21)
- Studies of the Molecular Mechanism of Discrimination between cGMP and cAMP in the Allosteric Sites of the cGMP-binding cGMP-specific Phosphodiesterase (PDE5)* (1999) (21)
- Cyclic AMP-dependent protein kinases from skeletal muscle and liver. (1972) (20)
- Phosphodiesterase-5 Inhibition (2004) (19)
- Allosteric-site and catalytic-site ligand effects on PDE5 functions are associated with distinct changes in physical form of the enzyme. (2009) (19)
- Phosphorylation of phosphodiesterase-5 is promoted by a conformational change induced by sildenafil, vardenafil, or tadalafil. (2007) (19)
- Isolated Regulatory Domains of cGMP-dependent Protein Kinase Iα and Iβ Retain Dimerization and Native cGMP-binding Properties and Undergo Isoform-specific Conformational Changes* (2006) (19)
- Phosphorylation Increases Affinity of the Phosphodiesterase-5 Catalytic Site for Tadalafil (2008) (18)
- Purification of cyclic nucleotide receptor proteins by cyclic nucleotide affinity chromatography. (1979) (18)
- Regulation of phosphoenolpyruvate carboxykinase gene transcription in H4IIE hepatoma cells: evidence for a primary role of the catalytic subunit of 3',5'-cyclic adenosine monophosphate-dependent protein kinase. (1987) (18)
- Two different intrachain cAMP sites in the cAMP-dependent protein kinase of the dimorphic fungus Mucor rouxii. (1989) (18)
- Purification of cAMP-free and cAMP-bound forms of bovine heart cAMP-dependent protein kinase holoenzyme. (1988) (18)
- Allosteric sites of phosphodiesterase-5 sequester cyclic GMP. (2004) (18)
- Cyclic AMP-dependent protein kinase isozymes of bovine epididymal spermatozoa: evidence against the existence of an ectokinase. (1986) (17)
- Precision Targeting of Protein Kinases (1996) (16)
- Using analogs to study selectivity and cooperativity of cyclic nucleotide binding sites. (1983) (16)
- Tyrosine-612 in PDE5 contributes to higher affinity for vardenafil over sildenafil (2006) (16)
- cAMP analogs used to study low-Km, hormone-sensitive phosphodiesterase. (1988) (16)
- Studies of functional domains of the regulatory subunit from cAMP-dependent protein kinase isozyme I. (1980) (16)
- The receptor protein for cyclic AMP in the control of glycogenolysis. (1970) (16)
- Mechanism and function of cAMP- and cGMP-dependent protein kinases. (1988) (15)
- Techniques for the study of protein kinase activation in intact cells. (1974) (14)
- 9 – Design and Synthesis of Xanthines and Cyclic GMP Analogues as Potent Inhibitors of PDE5 (1996) (14)
- Probing the Catalytic Sites and Activation Mechanism of Photoreceptor Phosphodiesterase Using Radiolabeled Phosphodiesterase Inhibitors* (2009) (13)
- Rat adipose tissue cAMP-dependent protein kinase: a unique form of type II (1984) (13)
- Characterization of the isolated cAMP‐binding B domain of cAMP‐dependent protein kinase (1995) (12)
- An assessment of phosphodiesterase activity in situ after treatment of hepatocytes with hormones. (1988) (12)
- Interactions between Cyclic Nucleotide Phosphodiesterase 11 Catalytic Site and Substrates or Tadalafil and Role of a Critical Gln-869 Hydrogen Bond (2009) (12)
- The Role of Cyclic AMP in the Action of Insulin (1968) (11)
- Calcineurin Regulates Homologous Desensitization of Natriuretic Peptide Receptor-A and Inhibits ANP-Induced Testosterone Production in MA-10 Cells (2012) (11)
- Structural order of the slow and fast intrasubunit cGMP-binding sites of type I alpha cGMP-dependent protein kinase. (1997) (10)
- Phosphorylation and activation of cGMP-dependent protein kinase by Src. (1998) (9)
- On the role of the cAMP and cGMP-dependent protein kinases in cell function. (1978) (9)
- Evidence that cyclic adenosine 3',5'-monophosphate-dependent protein kinase activation causes pig ovarian granulosa cell differentiation, including increases in two type II subclasses of this kinase. (1989) (9)
- Sildenafil (2019) (9)
- The pseudosubstrate sequences alone are not sufficient for potent autoinhibition of cAMP- and cGMP-dependent protein kinases as determined by synthetic peptide analysis. (1997) (8)
- Radiolabeled ligand binding to the catalytic or allosteric sites of PDE5 and PDE11. (2005) (8)
- Ser-27, Tyr-10 and Tyr-7 in the alpha-chain of pig stomach H+,K(+)-ATPase as Ca(2+)-dependent phosphorylatable sites by intrinsic and extrinsic protein kinases. (1996) (8)
- Comparison of cAMP and cGMP-dependent protein kinases. (1978) (7)
- Cyclic GMP Phosphodiesterases (2004) (6)
- Signal transduction in health and disease (1997) (6)
- DISTINGUISHING BETWEEN A MITOGENIC AND TWO CLOSELY RELATED NONMITOGENIC PROTEIN KINASES (1996) (6)
- Conformational conversion of PDE5 by incubation with sildenafil or metal ion is accompanied by stimulation of allosteric cGMP binding. (2011) (6)
- Control of Metabolic Processes by cAMP-Dependent Protein Phosphorylation (1976) (6)
- Effects of sildenafil on cAMP and cGMP levels in isolated human cavernous and cardiac tissue. (2000) (6)
- Distinguishing between Closely Related Protein Kinases: A Variation on the Bisubstrate Inhibitor Theme (1996) (6)
- Initiation and termination of cyclic nucleotide action (1988) (4)
- Metal ion stimulators of PDE5 cause similar conformational changes in the enzyme as does cGMP or sildenafil. (2011) (4)
- Purification of type I alpha and type I beta isozymes and proteolyzed type I beta monomeric enzyme of cGMP-dependent protein kinase from bovine aorta. (1991) (4)
- Effect of epinephrine or cAMP on cAMP-bound protein kinase holoenzymes in rat heart. (1991) (4)
- Regulation of Cyclic Nucleotide Levels by Sequestration (2010) (4)
- Adenylyl cyclase, G proteins, and guanylyl cyclase (1991) (3)
- Identifying protein kinases in crude extracts that phosphorylate cyclic GMP-binding cyclic-GMP specific phosphodiesterase. (1993) (3)
- Direct Involvement of the Cyclic Nucleotide Binding Sites in the Cyclic-Nucleotide-Induced Charge Shift of Protein Kinases (1990) (3)
- Tyrosine-612 in PDE5 contributes to higher affinity for vardenafil over sildenafil (2006) (3)
- CHAPTER 198 – Regulation of Cyclic Nucleotide Levels by Sequestration (2003) (3)
- Chapter 176 – Phosphodiesterase-5 (2010) (2)
- Activation of the type i beta isozyme of cgmp dependent protein kinase by preincubation with magnesium atp and camp (1992) (2)
- Initiation and termination of cyclic nucleotide action. I: Cyclic nucleotide cascades (1988) (2)
- Erratum: Pharmacotherapy for erectile dysfunction (Journal of Sexual Medicine (2004) vol. 1 (128) 10.1111/j.1743-6109.2004.04021.x) (2005) (2)
- Catalytic site amino acids of PKGI-alpha influence allosteric cGMP binding. (2013) (2)
- The Mechanism of Action of Cyclic AMP in the Activation of Phosphorylase Kinase (1972) (1)
- Two lobes and a cleft (1991) (1)
- Intracellular Receptors for cGMP and cAMP in Human Placenta. A11 (2000) (1)
- Sildenafil, pharmacology of a highly selective PDE5 inhibitor (2004) (1)
- Signal Transduction through cAMP and cGMP (1987) (1)
- Potent inhibition of phosphodiesterase‐5 (PDE5) by vardenafil, but not by sildenafil, tadalafil, or IBMX requires an intact GAF b domain (2006) (1)
- Stimulation of [3H]cIMP binding by cAMP analogs in extracts of perfused rat hearts. (1982) (1)
- Phosphorylation of Tyr7, Tyr10, and Ser27 of alpha-chain in H+,K(+)-ATPase by intrinsic and extrinsic kinases. (1997) (0)
- New features of PDE5 as revealed by a potent catalytic-site specific radioligand (2003) (0)
- Failure of insulin to antagonize cAMP-mediated glycogenolysis in rat ventricular cardiomyocytes. (1990) (0)
- Phosphorylation of Tyr7, Tyr10, and Ser27 of α‐Chain in H+,K+‐ATPase by Intrinsic and Extrinsic Kinases a (1997) (0)
- Cyclic GMP-binding, cyclic GMP-specific phosphodiesterasematerialer and Methods (1994) (0)
- Adenosine 3 ' : 5 '-cyclic monophosphate-and guanosine 3 ' : 5 '-cyclic monophosphate-dependent protein kinases : Possible homologous proteins ( protein phosphorylation / amino acid composition / substrate specificity / protein evolution ) (2003) (0)
- Erratum: (The Journal of Physiology (2002) vol. 545 (399-406)) (2003) (0)
- Initiation and termination of cyclic nucleotide action. VI: Methods for isolation and studies of various phosphodiesterase isoenzymes. A: Calmodulin-stimulated phosphodiesterase. B: cGMP-binding phosphodiesterases. C: High-affinity cAMP phosphodiesterases. D: Nonmammalian cyclic nucleotide phosphodi (1988) (0)
- Abstract 486: Down-regulation of type 1 cGMP-dependent Protein Kinase by the ubiquitin/proteasome pathway (2007) (0)
- Insulin action on exogenous cyclic nucleotide-stimulated adipocytes and hepatocytes (1984) (0)
- Crystal structure of PDE5A1-IBMX (2004) (0)
- Crystal structure of the catalytic domain of unliganded PDE5 (2006) (0)
- Identification of structural and functional features in human PDE5 regulatory domain that provide for allosteric cGMP binding and for dimerization (2003) (0)
- Initiation and termination of cyclic nucleotide action. V: General methods for studies of phosphodiesterases (1988) (0)
- Initiation and termination of cyclic nucleotide action. II: Assays of cyclic nucleotide levels, turnover, and transport (1988) (0)
- Purification and characterization of cGMP binding protein-phosphodiesterase from rat lung (1986) (0)
- In vivo and in vitro phosphorylation of rat liver fructose-1 , 6-bisphosphatase ( hexosediphosphatase / protein kinase / gluconeogenic enzyme / cyclic AMP ) (0)
- ANF elicits phosphorylation of the cGMP phosphodiesterase in vascular smooth muscle cells. (1998) (0)
- Phosphodiesterase type 5 inhibitors: molecular basis for pharmacological effects (2008) (0)
- Initiation and termination of cyclic nucleotide action. III: Cyclic nucleotide action. A: Cyclic nucleotide action in mammals. B: Nonmammalian cAMP binding proteins. C: Molecular genetic approaches (1988) (0)
- Multiple kinetic forms of phosophodiesterase‐5 (PDE5) are inter‐convertible in a regulatory domain‐dependent manner (2006) (0)
- A photoaffinity probe covalently modifies the catalytic site of the cGMP-binding cGMP-specific phosphodiesterase (PDE-5) (2007) (0)
- To the Editor of Nature Reviews Drug Discovery (2002) (0)
- Studies on the function of the two different intrachain cyclic AMP binding sites of heart protein kinase. (1982) (0)
- Union cyclic GMP, materials specific to cyclic GMP phosphodiesterase and methods. (1994) (0)
- PDE5 inhibition and fibrosis (2005) (0)
- Initiation and termination of cyclic nucleotide action. IV: Protein phosphatases (1988) (0)
- cGMP-Binding Phosphodiesterase: Novel Effects of cGMP Binding on the Interaction Between Functional Domains in the Enzyme (1990) (0)
- The Protein Kinase Family of Enzymes (2018) (0)
- CHAPTER 195 – Phosphodiesterase-5 (2003) (0)
- The Unexpected Evolution of Basic Science Studies about Cyclic Nucleotide Action into a Treatment for Erectile Dysfunction (2014) (0)
- vardenafil potency over sildenafil and tadalafil and is involved in PDE5 dimerization (2006) (0)
- Structure of PDE4D2-IBMX (2003) (0)
- Negative feedback control of the nitric oxide/cGMP pathway in smooth muscle (2007) (0)
- Mechanism of Action of Atrial Natriuretic Factor in the Adrenal Gland (1989) (0)
- Isolation of an inactive bovine heart cAMP-dependent protein kinase holoenzyme containing bound cAMP (1986) (0)
- Chapter 4 The biological functions of protein phosphorylation-dephosphorylation (1996) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Jackie D. Corbin?
Jackie D. Corbin is affiliated with the following schools:
